Global Virus Network (GVN) Announces Eight Distinguished International Appointments to Board of Directors

World Leaders in Business, Science, Law, Industry, Philanthropy & Government Are Committed to Supporting the GVN

Baltimore, MD, USA (April 6, 2021) – The Global Virus Network (GVN), a coalition of the world’s leading medical virology research centers working together to prevent illness and death from viral disease, today announced the election of eight distinguished global leaders to its Board of Directors.  They include Daniel J. Arbess, CIO of Xerion Investments, LLC and CEO of Xerion Precision Biosciences LLC;  Marc Bonneville, DVM, Scientific & Medical Director, Fondation Mérieux; Tomas Cihlar, PhD, Vice President, Virology, Gilead Sciences; Lan Kennedy-Davis, JD, Partner, RumbergerKirk; Yang Liu, PhD,  Chairman, Chief Executive Officer and Chief Scientific Officer, OncoC4, Inc and Adjunct Professor, Institute of Human Virology at the University of Maryland School of Medicine; David Scheer, President, Scheer & Company, Inc.; Yiming Shao, MD, PhD, Chief Expert on AIDS, Chinese Centre for Disease Control and Prevention, Vice Chair, Chinese Microbiology Society and Chair Professor, Zhejiang University; Pan Zheng, MD, PhD, Chief Medical Officer, OncoC4, Inc and Adjunct Professor, Institute of Human Virology at the University of Maryland School of Medicine.

The announcement was made today by Robert Gallo, MD, Co-founder and Director, Global Virus Network (GVN) and the Homer & Martha Gudelsky Distinguished Professor in Medicine, Co-founder and Director, Institute of Human Virology at the University of Maryland School of Medicine, a GVN Center of Excellence, Tim Moynahan, Chairman, The Moynahan Law Firm and Chairman, GVN Board of Directors and Christian Bréchot, MD, PhD, GVN President and Associate Vice President for International Partnerships and Innovation at University of South Florida (USF), Professor, Division of Infectious Disease, Department of Internal Medicine at the USF Health Morsani College of Medicine, the GVN Southeast U.S. Regional Headquarters.

“One of the biggest lessons we learned after discovering the first human retroviruses, including co-discovery of HIV as the cause of AIDS, and developing the HIV blood test, is that researchers need a GVN to share and disseminate important information seamlessly, without government politics or financial limitations,” said Dr. Robert Gallo.  “The current pandemic is yet another example of this urgent need, and I am pleased these new distinguished Board members value the work of the GVN from the past ten years and join us in our commitment to advance science and save lives.”

“I look forward to working with my fellow Board members and their expertise to advance the mission of the GVN,” said Tim Moynahan“Whether it is in the world of science, industry, law, government, business or philanthropy, each of these leaders and their expertise are essential global assets in the collective fight against viral threats around the world.”

“We are most pleased to welcome these distinguished new members to the GVN Board of Directors,” said Dr. Christian Bréchot“From the public to private sectors, GVN Board members contribute to the management of our organization and help grow our reach in both visibility and impact around the globe.”

“I am honored to contribute to GVN’s core mission of advancing collaborative science, global consensus, communication and pandemic preparedness,” said Daniel J. Arbess, CEO of Xerion Precision Biosciences, LLC.  Mr. Arbess is a multi-asset class investor, lawyer and social entrepreneur whose 35-year career has been defined by engagement as an adviser, investor and entrepreneur across of range of significant geopolitical, economic and healthcare developments.

“Joining the GVN network gives me the opportunity to learn more about this remarkable initiative and to participate in the major challenge of coordinating expertise to better prepare for future epidemics,” said Marc Bonneville, DVM, Scientific & Medical Director, Fondation Mérieux.  Dr. Bonneville is an accomplished immunologist with previous leadership positions at INSERM, Institut Mérieux and the Alliance for Research and Innovation of Healthcare Industries (ARIIS).

“I am excited to join the GVN board,” said Tomas Cihlar, PhD, Vice President, Virology, Gilead Sciences.   “It is dynamic and a quickly growing organization with a real impact not only on global virology science and education, but also on critical aspects of pandemic preparedness.”  Dr. Cihlar coordinates Gilead’s preclinical antiviral research across HIV, hepatitis, respiratory, and emerging viruses.  He has contributed to the development and regulatory approval of multiple antiviral therapies including many Gilead’s antiretrovirals and their combinations and led the preclinical and early clinical development of remdesivir.

“I am honored to work with such esteemed experts in their field and to be a part of GVN’s worldwide humanitarian efforts,” said Lan Kennedy-Davis, JD, Partner, RumbergerKirk.  Ms. Kennedy-Davis is a premier commercial litigation and corporate transactional attorney whose practice focuses on general and complex litigation and corporate transactions, including business and shareholder matters, intellectual property disputes, bankruptcy litigation and high stakes and assets family law cases. She has a strong business background, is an economist and a former business consultant to Fortune 500 companies and international entrepreneurs.

“We are so pleased to contribute our understanding of inflammation to a global effort to confront the heath challenges from viral infection,” said Yang Liu, PhD, Chairman, Chief Executive Officer and Chief Scientific Officer, OncoC4, Inc and Adjunct Professor, Institute of Human Virology at the University of Maryland School of Medicine.  Dr. Liu’s academic research includes the fundamental mechanisms of immune recognition, cell metabolism and cancer biology, and is a driving force in elucidating the mechanisms by which the innate immune system discriminates microbial infection and aseptic tissue injuries.

“I am proud to have been formally elected to serve on the Board of the GVN, an organization which has unique importance in the world today as we face the challenges of the current and potential future pandemics,” said David Scheer, President, Scheer & Company, Inc.  “I am particularly thrilled to work with the other members of the Board and with Bob Gallo, whom I have known since the late 1970s.” Mr. Scheer is an advisor and serial entrepreneur in the life sciences including building two antiviral drug development companies.  His career includes providing corporate strategic and transactional advisory services in the life sciences industry.  He also had a longstanding career in the global and public health arenas, working with some of the top researchers, thought-leaders.  He led a bioscience task force in Connecticut that gave rise to the Reopen CT Advisory Group, of which he served as a member, working with the State and its Governor to reopen in May of 2020.

“It is of paramount importance to keep a voice of independent virologists through the GVN in the era of viral pandemics and in a pan-politicized world,” said Yiming Shao, MD, PhD, Chief Expert on AIDS, Chinese Centre for Disease Control and Prevention, Vice Chair, Chinese Microbiology Society and Chair Professor, Zhejiang University.  “Only such a voice can help stop harmful, global conspiracies spreading during the COVID-19 pandemic and rightfully focus efforts to fight the virus together, instead of blaming each other.” Dr. Shao’s many accomplishments include isolating China’s first HIV strain, leading a national task force to build national laboratory networks for HIV diagnosis, molecular epidemiology and drug resistance surveillance, and conducting HIV vaccine research based on replicating vaccinia vector that concluded phase I/II clinical trials.  He serves on the WHO Vaccine Product Development for Vaccine Advisory Committee and HIV Cure Advisory Committee of International AIDS Society.

“We are delighted to be part of GVN to translate basic knowledge to clinical care of patients,” said Pan Zheng, MD, PhD, Chief Medical Officer, OncoC4, Inc and Adjunct Professor, Institute of Human Virology at the University of Maryland School of Medicine.  Dr. Zheng’s academic research focuses on immuno-oncology and inflammation. Dr. Zheng was trained in anatomic and clinical pathology and is a board-certified Physician with the American Board of Pathology.

Both Drs. Liu and Zheng co-founded OcnoImmune, Inc. until its acquisition by Merck, Inc. Drs. Liu and Zheng designed and executed the clinical trials for the company, including most recently a Phase III clinical trial, in conjunction with colleagues at the Institute of Human Virology at the University of Maryland School of Medicine, establishing strong therapeutic efficacy of CD24Fc for hospitalized severe and critical COVID-19 patients.

About the Global Virus Network (GVN)

The Global Virus Network (GVN) is essential and critical in the preparedness, defense and first research response to emerging, existing and unidentified viruses that pose a clear and present threat to public health, working in close coordination with established national and international institutions. It is a coalition comprised of eminent human and animal virologists from 62 Centers of Excellence and 11 Affiliates in 34 countries worldwide, working collaboratively to train the next generation, advance knowledge about how to identify and diagnose pandemic viruses, mitigate and control how such viruses spread and make us sick, as well as develop drugs, vaccines and treatments to combat them. No single institution in the world has expertise in all viral areas other than the GVN, which brings together the finest medical virologists to leverage their individual expertise and coalesce global teams of specialists on the scientific challenges, issues and problems posed by pandemic viruses. The GVN is a non-profit 501(c)(3) organization. For more information, please visit www.gvn.org. Follow us on Twitter @GlobalVirusNews

Media Contact:

Nora Samaranayake, GVN
[email protected]

INTERNATIONALLY RENOWNED VIROLOGIST CHRISTIAN BRÉCHOT APPOINTED PRESIDENT OF THE GLOBAL VIRUS NETWORK (GVN)

Brings Decades of Scientific & Organizational Leadership To Advance GVN’s Mission

Melbourne, Australia, September 25, 2017: The Global Virus Network (GVN), an international coalition of the world’s foremost medical virologists, comprising 40 Centers of Excellence in 24 countries, dedicated to identifying and researching, combatting and preventing, current and emerging pandemic viruses that pose a critical threat to public health and wellbeing, today announced the appointment of Christian Bréchot, MD, PhD as President of the GVN.  Dr. Bréchot, who recently stepped down as President of France’s internationally renowned Institut Pasteur, will assume his new position with the GVN effective October 1, 2017.  The announcement was made during the opening address of the 9th International Global Virus Meeting in Melbourne, Australia by Prof. Robert Gallo, MD, the GVN’s co-founder and scientific director, and by Prof. Sharon Lewin, MD, PhD, director of The Peter Doherty Institute for Infection and Immunity, a GVN Center of Excellence.

 

Said Dr. Gallo, who is also The Homer & Martha Gudelsky Distinguished Professor in Medicine and Director of the Institute of Human Virology at the University of Maryland School of Medicine, a GVN Center of Excellence, “When the GVN was founded in 2011, our mandate was to safeguard mankind from potential catastrophic and devastating pandemic virus by coalescing the finest public health expertise in order to undertake collaborative research, to train the next generation of virologists as well as to catalyze, engender and foment advocacy amongst leaders of government, the private sector and the scientific community throughout the world.  While we have made great strides in the last six years, having the unprecedented expertise, inspired vision and consummate leadership of Dr. Bréchot, a man of extraordinary ability in public health and basic science virology, will enable the GVN to fulfill its mandate and realize its ultimate potential for the betterment of mankind,” continued Dr. Gallo.

 

“When Bob introduced me to the GVN, I was impressed with the phenomenal caliber of virologists deeply engaged and committed to the vision of the organization,” said Dr. Bréchot.  “The world needs the GVN’s network of invaluable, diversified experts to be talking to each other, sharing information freely, and mitigating and preparing for viral threats.  The GVN is an invaluable and critical global resource.  I look forward to helping the GVN grow and develop, both operationally and financially as well as to working with Bob Gallo without whom the GVN would not be possible.”

 

Prof. Lewin said, “I joined the GVN because I agreed with my colleagues that there is a palpable need to engage with and empower the world’s foremost virologists to address current and future pandemic threats. I am thrilled that Dr. Gallo and I have the honor of making this important announcement at the 9th International Global Virus Meeting. We are enthusiastic about working with Dr. Bréchot and the GVN to defend mankind from dangerous and deadly viruses.”

 

Since October 2013, Dr. Bréchot has served as President of the Institut Pasteur developing programs to recruit eminent scientists, implementing an international multidisciplinary education and teaching program, fostering collaborative research and training strategies with major universities and research organizations, coalescing the international network of 33 Pasteur Institutes to encompass a global scientific vision and coordinated training activities, and positioning an ambitious and internationally oriented strategy for technology transfer and fundraising.

 

Dr. Bréchot held previous leadership positions with the French National Institute of Health and Medical Research (Inserm), the Institut Mérieux, and the BIOASTER Technology Research Institute. He previously served as a university professor, hospital practitioner, and head of departments of hepatology and cell biology.  In 1982, Dr. Bréchot received a Doctor of Medicine from Paris Descartes University (Paris VII) and a PhD in biochemistry from the Paris Descartes University.  Throughout his career, Dr. Bréchot’s research has focused on viral hepatitis B (HBV) and C (HCV), particularly regarding their role in liver cancer and to the molecular mechanisms that drive liver regeneration and cancer.  He is a member of numerous scientific committees and societies and has received a myriad of prestigious awards.  Dr. Bréchot has authored more than 350 articles published in prestigious medical and scientific journals.

 

Dr. Gallo, who conceived and co-founded the GVN with William Hall, PhD of University College Dublin and the late Reinhard Kurth, PhD, of the Robert Koch Institut in Germany, is distinguished and revered for co-discovering HIV as the cause of AIDS and for developing the HIV blood test, along with colleagues from the Institut Pasteur. The GVN concept began back in the 1980’s when a small group of medical virologists realized that virtually no working virologist had a global directive for researching the cause of AIDS during the earliest years of the epidemic.  Conversely, important groups such as the World Health Organization which did have a global mandate for combatting the new disease had virtually no resident expertise in the kind of virus that was subsequently shown to be the cause of AIDS, namely, a retrovirus.  Examining the history of other great epidemics of the 20th century, Influenza, Polio, and the more recent outbreak of SARS as well as several other viruses, reveals similar disconnects between available expertise and the urgent public need to identify causation and prevention modes.

 

About the Global Virus Network (GVN)

The Global Virus Network (GVN), a non-profit, 501(c)(3) organization, is an international coalition of the world’s foremost medical virologists, comprising 40 Centers of Excellence in 24 countries, dedicated to identifying and researching, combatting and preventing, current and emerging pandemic viruses that pose a critical threat to public health and wellbeing.  Founded in 2011, the GVN was founded to safeguard mankind from potential catastrophic and devastating pandemic virus by coalescing the finest public health expertise in order to undertake collaborative research, to train the next generation of virologists as well as to catalyze, engender and foment advocacy amongst leaders of government, the private sector and the scientific community throughout the world.  It is the world’s only network of top basic medical virologists from around the globe covering all classes of human viral threats.  For more information, please visit www.gvn.org. Follow us on Twitter @GlobalVirusNews

INTERNATIONALLY RENOWNED VIROLOGIST CHRISTIAN BRÉCHOT

APPOINTED PRESIDENT OF THE GLOBAL VIRUS NETWORK (GVN)

 

Brings Decades of Scientific & Organizational Leadership To Advance GVN’s Mission

 

Melbourne, Australia, September 25, 2017: The Global Virus Network (GVN), an international coalition of the world’s foremost medical virologists, comprising 40 Centers of Excellence in 24 countries, dedicated to identifying and researching, combatting and preventing, current and emerging pandemic viruses that pose a critical threat to public health and wellbeing, today announced the appointment of Christian Bréchot, MD, PhD as President of the GVN.  Dr. Bréchot, who recently stepped down as President of France’s internationally renowned Institut Pasteur, will assume his new position with the GVN effective October 1, 2017.  The announcement was made during the opening address of the 9th International Global Virus Meeting in Melbourne, Australia by Prof. Robert Gallo, MD, the GVN’s co-founder and scientific director, and by Prof. Sharon Lewin, MD, PhD, director of The Peter Doherty Institute for Infection and Immunity, a GVN Center of Excellence.

 

Said Dr. Gallo, who is also The Homer & Martha Gudelsky Distinguished Professor in Medicine and Director of the Institute of Human Virology at the University of Maryland School of Medicine, a GVN Center of Excellence, “When the GVN was founded in 2011, our mandate was to safeguard mankind from potential catastrophic and devastating pandemic virus by coalescing the finest public health expertise in order to undertake collaborative research, to train the next generation of virologists as well as to catalyze, engender and foment advocacy amongst leaders of government, the private sector and the scientific community throughout the world.  While we have made great strides in the last six years, having the unprecedented expertise, inspired vision and consummate leadership of Dr. Bréchot, a man of extraordinary ability in public health and basic science virology, will enable the GVN to fulfill its mandate and realize its ultimate potential for the betterment of mankind,” continued Dr. Gallo.

 

“When Bob introduced me to the GVN, I was impressed with the phenomenal caliber of virologists deeply engaged and committed to the vision of the organization,” said Dr. Bréchot.  “The world needs the GVN’s network of invaluable, diversified experts to be talking to each other, sharing information freely, and mitigating and preparing for viral threats.  The GVN is an invaluable and critical global resource.  I look forward to helping the GVN grow and develop, both operationally and financially as well as to working with Bob Gallo without whom the GVN would not be possible.”

 

Prof. Lewin said, “I joined the GVN because I agreed with my colleagues that there is a palpable need to engage with and empower the world’s foremost virologists to address current and future pandemic threats. I am thrilled that Dr. Gallo and I have the honor of making this important announcement at the 9th International Global Virus Meeting. We are enthusiastic about working with Dr. Bréchot and the GVN to defend mankind from dangerous and deadly viruses.”

 

Since October 2013, Dr. Bréchot has served as President of the Institut Pasteur developing programs to recruit eminent scientists, implementing an international multidisciplinary education and teaching program, fostering collaborative research and training strategies with major universities and research organizations, coalescing the international network of 33 Pasteur Institutes to encompass a global scientific vision and coordinated training activities, and positioning an ambitious and internationally oriented strategy for technology transfer and fundraising.

 

Dr. Bréchot held previous leadership positions with the French National Institute of Health and Medical Research (Inserm), the Institut Mérieux, and the BIOASTER Technology Research Institute. He previously served as a university professor, hospital practitioner, and head of departments of hepatology and cell biology.  In 1982, Dr. Bréchot received a Doctor of Medicine from Paris Descartes University (Paris VII) and a PhD in biochemistry from the Paris Descartes University.  Throughout his career, Dr. Bréchot’s research has focused on viral hepatitis B (HBV) and C (HCV), particularly regarding their role in liver cancer and to the molecular mechanisms that drive liver regeneration and cancer.  He is a member of numerous scientific committees and societies and has received a myriad of prestigious awards.  Dr. Bréchot has authored more than 350 articles published in prestigious medical and scientific journals.

 

Dr. Gallo, who conceived and co-founded the GVN, is distinguished and revered for co-discovering HIV as the cause of AIDS and for developing the HIV blood test, along with colleagues from the Institut Pasteur.  The GVN concept began back in the 1980’s when a small group of medical virologists realized that virtually no working virologist had a global directive for researching the cause of AIDS during the earliest years of the epidemic.  Conversely, important groups such as the World Health Organization which did have a global mandate for combatting the new disease had virtually no resident expertise in the kind of virus that was subsequently shown to be the cause of AIDS, namely, a retrovirus.  Examining the history of other great epidemics of the 20th century, Influenza, Polio, and the more recent outbreak of SARS as well as several other viruses, reveals similar disconnects between available expertise and the urgent public need to identify causation and prevention modes.

 

Prominent Virologist Stanley Plotkin Joins GVN as Senior Advisor

Baltimore, MD: January 14, 2014 ;The Global Virus Network (GVN) is honored to have Dr. Stanley A. Plotkin, Emeritus Professor of the University of Pennsylvania and consultant to all of the major vaccine manufacturers, serve as a senior advisor. Dr. Plotkin is world renowned for his development of the rubella vaccine- now in standard use throughout the world, and has worked extensively on the development and application of other vaccines including polio, rabies, varicella, rotavirus and cytomegalovirus.

 
“I am happy to join such a distinguished group of virologists,” said Dr. Plotkin.
 
“Stan is one of the most experienced and wisest of virologists who will be invaluable to the GVN objectives,” said GVN co-founder and scientific director Dr. Robert Gallo.
 
“Stan’s encyclopedic knowledge of viruses and their modes of transmission will be of enormous help in guiding the Scientific Leadership Board of GVN when decisions have to be made to limit the expansion of existing epidemics or curb the outbreak of newly emerging viruses,” said fellow GVN co-founder, Dr. Reinhard Kurth, Chairman of the Foundation Council, Ernst Schering Foundation in Berlin, Germany.
 

Gallo reflects on 30 years in HIV research

Gallo reflects on 30 years in HIV research

 

Dan Rodricks, of the Baltimore Sun in January 4 th interview of Dr. Robert Gallo, and discusses the current advances leading to a “functional cure” .

Gallo Speaks to Dan Rodricks

Dr. Gallo spoke about the beginning of AIDS, the need for the next generation of trained virologists, the creation of the Global Virus Network, viruses in general, IHV’s HIV preventive vaccine candidate, a PEPFAR for the U.S., among other important issues.  At the end, the reporter thanks Gallo and his team for choosing the University of Maryland. If you get a moment, please tune in here: http://programs.wypr.org/podcast/dr-robert-gallo-thurs-december-19-12-1-pm

Distinguished Attorney Timothy C. Moynahan Named Chairman of the Global Virus Network (Gvn) Board of Directors

DISTINGUISHED ATTORNEY TIMOTHY C. MOYNAHAN NAMED CHAIRMAN OF THE GLOBAL VIRUS NETWORK (GVN) BOARD OF DIRECTORS

Will Forge Partnerships With Multinational Corporations & Private Benefactors To Mitigate The Threat & Financial Impact Of Pandemic Viral Diseases

Baltimore, MD (December 17, 2013) – The Global Virus Network (GVN), a coalition of the world’s foremost medical virology research centers working to prevent illness and death from pandemic viruses, today announced that Timothy C. Moynahan, Esq., has been elected as the 2014 Chairman of the Board of Directors.  The announcement was made by Robert C. Gallo, MD, co-founder of the GVN, Chair of GVN’s Scientific Leadership Board, and Director of the Institute of Human Virology at the University of Maryland School of Medicine in Baltimore, Maryland, USA.  Dr. Gallo was joined in this announcement by GVN co-founders Reinhard Kurth, MD, Chairman of the Foundation Council, Ernst Schering Foundation in Berlin, Germany and William Hall, MD, PhD, Vice Chair of the GVN Board of Directors, and Director of the Centre for Research in Infectious Diseases the University College Dublin in Ireland.  Mr. Moynahan takes on the Chairman’s role from immediate past Chairman G. Steven Burrill, CEO of Burrill & Company.

“Mr. Moynahan brings a wealth of knowledge and expertise on international business and public-private sector partnerships to the GVN,” said Dr. Gallo, most notably known for his co-discovery of HIV and development of the blood test. “We are confident that Mr. Moynahan will lead the Board with vision  and passion for GVN’s critical mission of safeguarding life from potentially pandemic viral disease,” he added.   Mr. Moynahan served as the first Chairman of the GVN Board of Directors at the time of the GVN’s establishment in 2011.  “Tim’s insights into GVN as a founding Board member and as its inaugural Chairman position him perfectly to lead us successfully into the future,” continued Dr. Gallo.

One of Mr. Moynahan’s primary objectives is to develop partnerships with relevant multinational corporations and private benefactors in order to provide the substantial funding required to address the serious threat and exorbitant financial impact posed by potentially pandemic viral disease threatening public health.  “I am honored to serve as GVN’s Chairman once again and work alongside my dedicated and distinguished colleagues,” said Mr. Moynahan.  “Viruses continue to take tragic tolls on humanity in many ways, with millions of lives lost each year and staggering costs to the global economy.  The current flu season is a stark reminder:  According to the World Health Organization, seasonal flu in the United States alone results in 40,000 deaths and $87.1 billion in economic losses, both directly in terms of health care, and indirectly through work days lost and other factors.   One of my most important mandates is to raise awareness of the staggering impact of viruses on lives, commerce and businesses,” he added.

Mr. Moynahan, a preeminent litigation attorney, is the founder of The Moynahan Law Firm, one of Connecticut’s most respected law firms.   In addition to his role as Chairman of the Board of the Global Virus Network, Mr. Moynahan has been elected to the board of directors of numerous corporations and charitable organizations, including the Post University MBA Advisory Council, the Advisory Board of the Institute of Human Virology, the International Network for Cancer Treatment and Research (INCTR) and President of the Connecticut Chapter of the Ireland Chamber of Commerce in the United States.

GVN Co-Founder William Hall Receives Prestigious Vietnamese Honor

GVN Co-Founder William Hall Receives Prestigious Vietnamese Honor

In a ceremony in Hanoi this month, GVN Co-Founder William Hall of University College Dublin, Ireland and Director of the Atlantic Philanthropies (AP), was presented an insignia award by the Vietnam Union of Friendship Organisations (VUFO) for his immense efforts and contributions to the development of the Vietnamese health and education systems as well as to the country’s poverty reduction.  Dr. Hall’s efforts since 2007 with the Ireland Vietnam Blood-Borne Virus Initiative (IVVI), a collaboration with the University College Dublin – a GVN Center of Excellence – has led to, nine Vietnamese students completing the program, three of whom are GVN Scholars.  When receiving the honor, Dr. Hall said he considers Vietnam his second home and will continue his efforts in building Vietnam’s public health and education infrastructures.  For more information, please refer to the cover article in GVN’s latest Virion newsletter.

Link to announcement 

 

Munich Meeting Discussion

The following are comments from the Munich Meeting.